The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
mRNA vaccines — a new era in vaccinology
Open accessAbstract
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA production and lipid nanoparticle formulation are fast and highly scalable, which renders this technology suitable for the rapid development and supply of vaccines during pandemic scenarios 11,12 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“samRNA vaccines can induce potent immune responses at lower doses due to their ability to amplify antigen production within the body, potentially reducing the risk of adverse reactions6,44.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The technique can be easily scaled requiring minimum platform changes during mRNA formulation and production (Pardi et al. 2018).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Pardi et al. 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The mRNA also does not interact with the genome and only the parts directly required for the encoded protein expression are present in this basic genetic construct (Pardi et al. 2018).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Pardi et al. 2018
In the citing paper
“Both BNT162b2 and mRNA-1273, as well as the adenoviral-vectored vaccine ChAdOx1 nCoV-19, have been shown to induce type I interferon, thus potentially inducing pathogen-agnostic protection75–77.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [75]
In the citing paper
“Non-replicating mRNA vaccines deliver exclusively genetic information coding for the target antigen, thus containing the 5′-cap, 5′ untranslated region (UTR), 3′ UTR, and 3′-poly(A) tail regions.108”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [108]
In the citing paper
“Furthermore, the upscaling of cell-free vaccine production is relatively straightforward, thereby providing a cutting-edge tool for rapid response in epidemics and pandemics.4, 5, 6, 7”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [5]
In the citing paper
“Unlike some viral vaccines, mRNA does not integrate into the genome, obviating concerns about insertional mutagenesis5.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [5]
In the citing paper
“The use of modified nucleosides, particularly modified uridine, prevents recognition by pattern recognition receptors, enabling sufficient levels of translation to produce prophylactic amounts of protein5.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [5]
In the citing paper
“although it has been employed for various therapeutic targets, its use as a source of antigen in vaccination approaches is by far the most popular [2]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [2]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“mRNA is susceptible to degradation and, thus, formulation buffers should be free of any ribonuclease contaminations2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Many other lipid nanoparticle–mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders2,4,8,12–14 (Tables 1,2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“These features make lipid nanoparticle–mRNA formulations a flexible and on-demand vaccine platform to rapidly respond to emerging infectious pathogens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Since then, lipid nanoparticle–mRNA formulations have emerged as a potent alternative to conventional vaccine platforms, owing to their unique features4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Moreover, mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies2,4,8,12–14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“First, mRNA is a non-infective and non-integrating agent with the ability to encode a broad range of antigens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Neoantigens are often different between individual patients, allowing the development of personalized vaccines4,11.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Neoantigens, generated by somatic mutations in cancer cells, are usually tumour-specific and have high immunogenicity4,11.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“The sequences of these elements regulate translation initiation, translation termination and post-transcriptional modification of mRNA molecules2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“To achieve effective translation, mRNA requires five structural elements, including the 5′ cap, 3′ poly(A) tail, protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“the application of RNA vaccines has been limited by their lack of stability and requirement for a cold chain”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [131]
In the citing paper
“RNA vaccines, for example, have exhibited encouraging results in both infection therapy and cancer immunotherapy.[6, 7, 11–15]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [12]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Johnston, R. J., Poholek, A. C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent, A. L., Craft, J., & Crotty, S. (2009) · Science · doi:10.1126/science.1175870 · Cited by 1,626
Bcl6 mediates the development of T follicular helper cells
Nurieva, R. I., Chung, Y., Martinez, G. J., Yang, X. O., Tanaka, S., Matskevitch, T. D., Wang, Y.-H., & Dong, C. (2009) · Science · doi:10.1126/science.1176676 · Cited by 1,506
Flagged first, then by citations
1 of the 218 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–1,000 of 1,011
mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer
Malla, R. R., Srilatha, M., Farran, B., & Nagaraju, G. P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.024 · Cited by 51
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines
Lim, C. M. L., Komarasamy, T. V., Adnan, N. A. A., Radhakrishnan, A. K., & Balasubramaniam, V. R. M. T. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13276 · Cited by 55
Hwang, Y., Shepherd, S. J., Kim, D., Mukalel, A. J., Mitchell, M. J., Issadore, D. A., & Lee, D. (2024) · ACS Nano · doi:10.1021/acsnano.4c12965 · Cited by 50
mRNA vaccines in the context of cancer treatment: from concept to application
Fu, Q., Zhao, X., Hu, J., Jiao, Y., Yan, Y., Pan, X., Wang, X., & Jiao, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06033-6 · Cited by 59
Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
Li, H., Hu, Y., Li, J., He, J., Yu, G., Wang, J., & Lin, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02191-1 · Cited by 56
Vaccines and Therapies in Development for SARS-CoV-2 Infections
Wu, D. B.-C., Koganti, R., Lambe, U. P., Yadavalli, T., Nandi, S. S., & Shukla, D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061885 · Cited by 47
Structural components for amplification of positive and negative strand VEEV splitzicons
Blakney, A. K., McKay, P. F., & Shattock, R. J. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00071 · Cited by 47
Ayad, C., Libeau, P., Lacroix, C., Ladavière, C., & Verrier, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030377 · Cited by 48
Schijns, V. E. C. J., Majhen, D., van der Ley, P., Thakur, A., Summerfield, A., Berisio, R., Nativi, C., Fernández‐Tejada, A., Alvarez-Domı́nguez, C., Gizurarson, S. S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040501 · Cited by 52
From Lock-In to Transformation: A Path-Centric Theory of Emerging Technology and Organizing
Pentland, B. T., Yoo, Y., Recker, J., & Kim, I. (2021) · Organization Science · doi:10.1287/orsc.2021.1543 · Cited by 47
Bellavite, P., Ferraresi, A., & Isidoro, C. (2023) · Biomedicines · doi:10.3390/biomedicines11020451 · Cited by 50
Computational design of mRNA vaccines
Kim, Y.-A., Mousavi, K., Yazdi, A. K., Zwierzyna, M., Cardinali, M., Fox, D. M., Peel, T., Coller, J., Aggarwal, K., & Maruggi, G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.024 · Cited by 47
Kubara, K., Yamazaki, K., Miyazaki, T., Kondo, K., Kurotaki, D., Tamura, T., & Suzuki, Y. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.020 · Cited by 51
Metanat, Y., Viktor, P., Amajd, A., Kaur, I., Hamed, A. M., Al-Abadi, N. K. A., Alwan, N. H., Chaitanya, M., Natrayan, L., Ghildiyal, P., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122683 · Cited by 49
Bouzid, R., Peppelenbosch, M. P., & Buschow, S. I. (2020) · Cancers · doi:10.3390/cancers12051121 · Cited by 46
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2020) · Molecules · doi:10.3390/molecules25245995 · Cited by 49
Toy, R., Pradhan, P., Ramesh, V., Paolo, N. C. D., Lash, B., Liu, J., Blanchard, E. L., Pinelli, C. J., Santangelo, P. J., Shayakhmetov, D. M., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119512 · Cited by 46
Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges
Ahmad, M. Z., Ahmad, J., Haque, A., Alasmary, M. Y., Abdel‐Wahab, B. A., & Akhter, S. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1858058 · Cited by 47
Novel suction-based in vivo cutaneous DNA transfection platform
Lallow, E. O., Jhumur, N. C., Ahmed, I., Kudchodkar, S. B., Roberts, C. C., Jeong, M., Melnik, J. M., Park, S. H., Muthumani, K., Shan, J. W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0611 · Cited by 46
mRNA Vaccines: Why Is the Biology of Retroposition Ignored?
Domazet‐Lošo, T. (2022) · Genes · doi:10.3390/genes13050719 · Cited by 47
Duan, X., Zhang, Y., Guo, M., Fan, N., Chen, K., Qin, S., Xiao, W., Zheng, Q., Huang, H., Wei, X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.015 · Cited by 46
Schmid, P., & Betsch, C. (2022) · Science Communication · doi:10.1177/10755470221129608 · Cited by 44
Potential health risks of mRNA-based vaccine therapy: A hypothesis
Acevedo‐Whitehouse, K. A., & Bruno, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111015 · Cited by 56
mRNA delivery in cancer immunotherapy
Zhong, Y., Du, S., & Dong, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.001 · Cited by 49
Takanashi, A., Pouton, C. W., & Al-Wassiti, H. A. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01024 · Cited by 48
The Platform Technology Approach to mRNA Product Development and Regulation
Skerritt, J. H., Tucek, C. L., Sutton, B. A., & Nolan, T. M. (2024) · Vaccines · doi:10.3390/vaccines12050528 · Cited by 49
Kawai, A., Shimizu, T., Tanaka, H., Shichinohe, S., Anindita, J., Hirose, M., Kawahara, E., Senpuku, K., Shimooka, M., Mai, L. T. Q., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.12.032 · Cited by 49
Exogenous RNA surveillance by proton-sensing TRIM25
Kim, M., Pyo, Y., Hyun, S., Jeong, M., Choi, Y., & Kim, V. N. (2025) · Science · doi:10.1126/science.ads4539 · Cited by 49
Bernelin‐Cottet, C., Urien, C., McCaffrey, J., Collins, D., Donadei, A., McDaid, D., Jakob, V., Barnier-Quer, C., Collin, N., Bouguyon, E., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.041 · Cited by 47
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
Cai, X., Li, J. J., Liu, T., Brian, O., & Li, J. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab027 · Cited by 47
Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications
Chuang, S. T., Conklin, B., Stein, J. B., Pan, G., & Lee, K. (2022) · Nano Convergence · doi:10.1186/s40580-022-00310-0 · Cited by 48
Mahroum, N., Lavine, N., Ohayon, A., Seida, R., Alwani, A., Alrais, M., Zoubi, M., & Bragazzi, N. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872683 · Cited by 50
Toward rational vaccine engineering
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114142 · Cited by 45
Yin, J., Chen, Y., Li, Y., Wang, C., & Zhang, X. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.005 · Cited by 45
Tang, X., Huo, M., Chen, Y., Huang, H., Qin, S., Luo, J., Qin, Z., Jiang, X., Liu, Y., Duan, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.003 · Cited by 47
Shi, R., Liu, X., Wang, Y., Pan, M., Wang, S., Shi, L., & Ni, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2342592 · Cited by 48
Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases
Moosavi, S. G., Rahiman, N., Jaafari, M. R., & Arabi, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113641 · Cited by 54
Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation
Bishoyi, A. K., Nouri, S., Hussen, A., Bayani, A., Khaksari, M. N., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01686-z · Cited by 48
From micro to nano: evolution and impact of drug delivery in treating disease
Hrkach, J., & Langer, R. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00769-6 · Cited by 45
Begum, J., Mir, N. A., Dev, K., Buyamayum, B., Wani, M. Y., & Raza, M. (2020) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13804 · Cited by 44
mRNA Vaccines against Flaviviruses
Wollner, C. J., & Richner, J. M. (2021) · Vaccines · doi:10.3390/vaccines9020148 · Cited by 44
Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
Çakır, M., Obernier, K., Forget, A., & Krogan, N. J. (2021) · mSystems · doi:10.1128/msystems.00388-21 · Cited by 45
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Kis, Z., Tak, K., Ibrahim, D., Papathanasiou, M. M., Chachuat, B., Shah, N., & Kontoravdi, C. (2022) · npj Vaccines · doi:10.1038/s41541-022-00447-3 · Cited by 52
New opportunities for immunomodulation of the tumour microenvironment using chemical tools
Su, J., Li, W., & Li, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00486k · Cited by 44
Strategy of developing nucleic acid-based universal monkeypox vaccine candidates
Papukashvili, D., Rcheulishvili, N., Liu, C., Wang, X., He, Y., & Wang, P. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050309 · Cited by 45
RNAdegformer: accurate prediction of mRNA degradation at nucleotide resolution with deep learning
He, S., Gao, B., Sabnis, R., & Sun, Q. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac581 · Cited by 47
Tilapia Lake Virus Vaccine Development: A Review on the Recent Advances
Kembou-Ringert, J. E., Steinhagen, D., Readman, J., Daly, J. M., & Adamek, M. (2023) · Vaccines · doi:10.3390/vaccines11020251 · Cited by 44
mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles
Adlsadabad, S. Y., Hanrahan, J. W., & Kakkar, A. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031739 · Cited by 47
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges
Bandara, S., & Raveendran, S. (2025) · Cancers · doi:10.3390/cancers17050821 · Cited by 56
Polymers and hydrogels for local nucleic acid delivery
Fliervoet, L. A. L., Engbersen, J. F. J., Schiffelers, R. M., Hennink, W. E., & Vermonden, T. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01795f · Cited by 44
RNA Therapeutics: How Far Have We Gone?
Coutinho, M. F., Matos, L., Santos, J. I., & Alves, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-19966-1_7 · Cited by 45
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy
García-Fernández, C., Fornaguera, C., & Borrós, S. (2020) · Cancers · doi:10.3390/cancers12061609 · Cited by 44
Pharmacological Treatment of Secondary Lymphedema
Brown, S., Dayan, J. H., Coriddi, M. R., Campbell, A.-C., Kuonqui, K. G., Shin, J., Park, H. J., Mehrara, B. J., & Kataru, R. P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.828513 · Cited by 44
Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 45
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases
Kronbichler, A., Anders, H., Juarez, G. M. F., Floege, J., Goumenos, D. S., Segelmark, M., Tesař, V., Türkmen, K., van Kooten, C., & Bruchfeld, A. N. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab064 · Cited by 46
Fine-tuning of polyaspartamide derivatives with alicyclic moieties for systemic mRNA delivery
Yum, J., Kim, B. S., Ogura, S., Kamegawa, R., Naito, M., Yamasaki, Y., Kim, H. J., & Miyata, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.040 · Cited by 43
Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 45
Lipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 43
Mohite, P. B., Yadav, V., Pandhare, R., Maitra, S., Saleh, F. M., Saleem, R. M., Al-malky, H. S., Kumarasamy, V., Subramaniyan, V., Abdel‐Daim, M. M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.3c06501 · Cited by 47
Li, W., Li, Y., Li, J., Meng, J., Jiang, Z., Chen, Y., Wen, Y., Liu, S., Cheng, X., Mi, S., et al. (2024) · Advanced Science · doi:10.1002/advs.202309770 · Cited by 44
Brook, B., Duval, V., Barman, S., Speciner, L., Sweitzer, C., Khanmohammed, A., Menon, M., Foster, K., Ghosh, P., Abedi, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adm8451 · Cited by 49
Eftekhari, Z., Zohrabi, H., Oghalaie, A., Ebrahimi, T., Shariati, F. S., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102313 · Cited by 46
Advances and applications of RNA vaccines in tumor treatment
Yang, R., & Cui, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02141-5 · Cited by 48
Revolutionizing Nanovaccines: A New Era of Immunization
Saleh, M. A., El-Moghazy, A. Y., El-Gohary, A. H., Saber, W. I. A., & Helmy, Y. A. (2025) · Vaccines · doi:10.3390/vaccines13020126 · Cited by 52
Nanocarriers for cutting-edge cancer immunotherapies
Hu, J. K., Arvejeh, P. M., Bone, S., Hett, E. C., Marincola, F. M., & Roh, K. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06435-0 · Cited by 48
Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 47
Kumar, G., & Ardekani, A. M. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01716 · Cited by 48
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses
Castaño, D., Bettini, E., Kumar, B., Chudnovskiy, A., Siv, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Luna, N. D., Chiu, J. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.023 · Cited by 44
Self-citationThe Rocky Road From Fed-Batch to Continuous Processing With E. coli
Kopp, J., Slouka, C., Oliver Spadiut, A., & Herwig, C. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00328 · Cited by 45
Self-disseminating vaccines to suppress zoonoses
Nuismer, S. L., & Bull, J. J. (2020) · Nature Ecology & Evolution · doi:10.1038/s41559-020-1254-y · Cited by 43
Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials
Tang, J., Li, M., Zhao, C., Shen, D., Liu, L., Zhang, X., & Wei, L. (2022) · Viruses · doi:10.3390/v14020239 · Cited by 48
Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 45
Biomaterials and nanomaterials for sustained release vaccine delivery
Luzuriaga, M. A., Shahrivarkevishahi, A., Herbert, F. C., Wijesundara, Y. H., & Gassensmith, J. J. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1735 · Cited by 41
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 45
N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs
Chen, T.-H., Potapov, V., Dai, N., Ong, J. L., & Roy, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-17249-1 · Cited by 44
An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs
Li, J., Liu, Q., Liu, J., Wu, X., Lei, Y., Li, S., Zhao, D., Li, Z., Luo, L., Peng, S., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01919-7 · Cited by 46
Bioinspired Lipid Nanocarriers for RNA Delivery
Golubovic, A., Tsai, S., & Li, B. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00073 · Cited by 49
Rohde, C. M., Lindemann, C., Giovanelli, M. A., Sellers, R. S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A. B., Chervona, Y., Muik, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020417 · Cited by 44
Advanced nano-based strategies for mRNA tumor vaccine
Qu, Y., Xu, J., Zhang, T., Chen, Q., Sun, T., & Jiang, C. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.025 · Cited by 42
Recent advances in nano- and micro-scale carrier systems for controlled delivery of vaccines
Wang, E. Y., Sarmadi, M., Ying, B., Jaklenec, A., & Langer, R. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122345 · Cited by 42
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 44
Porcine Epidemic Diarrhea: Insights and Progress on Vaccines
Park, J.-E. (2024) · Vaccines · doi:10.3390/vaccines12020212 · Cited by 42
Chaudhary, N., Newby, A. N., Arral, M. L., Yerneni, S. S., LoPresti, S. T., Doerfler, R., Petersen, D. M. S., Montoya, C., Kim, J. S., Fox, B., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307810121 · Cited by 49
Maeki, M., Kimura, N., Okada, Y., Shimizu, K., Shibata, K., Miyazaki, Y., Ishida, A., Yonezawa, K., Shimizu, N., Shinoda, W., et al. (2024) · Nanoscale Advances · doi:10.1039/d3na01073b · Cited by 43
Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology
Jacob, E. M., Huang, J., & Chen, M. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae017 · Cited by 48
Bathula, N. V., Friesen, J. J., Casmil, I. C., Wayne, C. J., Liao, S., Soriano, S. K. V., Ho, C.-H., Strumpel, A., & Blakney, A. K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.078 · Cited by 44
Current Analytical Strategies for mRNA-Based Therapeutics
Camperi, J., Chatla, K., Freund, E. C., Galan, C., Lippold, S., & Guilbaud, A. (2025) · Molecules · doi:10.3390/molecules30071629 · Cited by 47
Nucleic acid-based therapy for coronavirus disease 2019
Piyush, R., Rajarshi, K., Chatterjee, A., Khan, R., & Ray, S. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05007 · Cited by 44
Ishaqat, A., & Herrmann, A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08484 · Cited by 42
Njoga, E. O., Mshelbwala, P. P., Abah, K. O., Awoyomi, O. J., Wangdi, K., Pewan, S. B., Oyeleye, F. A., Galadima, H. B., Alhassan, S. A., Okoli, C. E., et al. (2022) · Vaccines · doi:10.3390/vaccines10040626 · Cited by 40
Current strategies employed in the manipulation of gene expression for clinical purposes
Tsai, H., Pietrobon, V., Peng, M., Wang, S., Zhao, L., Marincola, F. M., & Cai, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03747-3 · Cited by 48
Zhou, P., Liu, W., Cheng, Y., & Qian, D. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1718 · Cited by 42
Rahimnejad, M., Rabiee, N., Ahmadi, S., Jahangiri, S., Sajadi, S. M., Akhavan, O., Saeb, M. R., Kwon, W., Kim, M., & Hahn, S. K. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00932 · Cited by 44
Lipid-Based Nanocarrier Systems for Drug Delivery: Advances and Applications
Zhao, Y., Li, L., Zhou, E.-F., Wang, J., Wang, Y., Guo, L., & Zhang, X. (2022) · Pharmaceutical Fronts · doi:10.1055/s-0042-1751036 · Cited by 50
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Nham, E., Song, J. Y., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e351 · Cited by 42
Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Zhao, Y., Gan, L., Ke, D., Chen, Q., & Fu, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04553-1 · Cited by 45
Design and lyophilization of mRNA-encapsulating lipid nanoparticles
Wang, T., Yu, T., Li, W., Liu, Q., Sung, T., & Higuchi, A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124514 · Cited by 42
Strong Immune Responses Induced by Direct Local Injections of Modified mRNA-Lipid Nanocomplexes
Arya, S., Lin, Q., Zhou, N., Gao, X., & Huang, J.-D. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.12.044 · Cited by 39
Metadata
- Authors
- Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Corresponding author
- Weissman, Drew
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-01-12
- Volume
- 17
- Issue
- 4
- Pages
- 261-279
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC5906799
- OpenAlex
- W2782708334
- Cited by
- 4,667
- References
- 218
- Citations by year
- 2026: 640 · 2025: 683 · 2024: 630 · 2023: 662 · 2022: 801 · 2021: 808 · 2020: 303 · 2019: 90 · 2018: 49
- FWCI
- 30.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bill and Melinda Gates Foundation (OPP1066832, OPP1033102)
- National Institutes of Health (AI084860, AI-100645)
- Defense Advanced Research Projects Agency (HR0011‐17‐2‐0069)
- Advanced Research Projects Agency
- National Institute of Allergy and Infectious Diseases (AI-100645, UM1AI100645, R01-AI084860, R01AI050484, R01AI124429, AI124429, U01AI067854, R01AI090788)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- mRNA vaccines, mRNA stability, mRNA delivery, vaccine platforms, cancer vaccines, infectious disease vaccines, vaccine development
- MeSH terms
- Vaccinology, Animals, Humans, Neoplasms, RNA, Messenger, Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
